Skip to content
NVCTNuvectis Pharma, Inc.

Earnings

When Nuvectis Pharma, Inc. reports, what it reported each quarter, and how the stock took the results.

23 quarters. Mar 31, 2021 to Sep 30, 2026. mixed units.

Next results · Q4 2026Projected

Feb 10, before the open

Wed, Feb 10, 2027in 84 days

Projected from its last 8 releases. The company has not named the day yet.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Feb 8 – Mar 26

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
—
Net income
-$7.31M
Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
EPS
—
EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m

Quarter by quarter

Q3 2026-$30.07MNo Q3 2025 on file

Latest results

  1. Q3 2026Nov 4, 2026, before the openThe release4.9%by the close of Nov 4
    Revenue
    —
    —
    Net income
    -$30.07M
    N/M
    EPS
    -$1.02
    N/M
    Completed in licensing of two potentially best-in-class drug candidates from Haisco Pharmaceutical Group and follow-on public offering anchored by leading healthcare investors.
  2. Q2 2026Aug 4, 2026, before the openThe release6.7%by the close of Aug 4
    Revenue
    —
    —
    Net income
    -$7.02M
    N/M
    EPS
    -$0.30
    N/M
  3. Q1 2026May 5, 2026, before the openThe release+9.2%by the close of May 5
    Revenue
    —
    —
    Net income
    -$6.05M
    N/M
    EPS
    -$0.26
    N/M
  4. Q4 2025Feb 11, 2026, before the openThe release+0.2%by the close of Feb 11
    Revenue
    —
    —
    Net income
    -$7.31M
    N/M
    EPS
    —
    —

All quarters

PeriodEndedAnnouncedFiledLagFormRevenueΔ yoyEPS dil.MoveSource trail
FY 2026
Q3 2026Sep 30, 2026Nov 4, 2026 · pre-marketNov 4, 202635 d10-Q——-$1.024.9%
Q2 2026Jun 30, 2026Aug 4, 2026 · pre-marketAug 4, 202635 d10-Q——-$0.306.7%
Q1 2026Mar 31, 2026May 5, 2026 · pre-marketMay 5, 202635 d10-Q——-$0.26+9.2%
FY 2025
Q4 2025derivedDec 31, 2025Feb 11, 2026 · pre-marketFeb 11, 202642 d10-K———+0.2%
Q3 2025Sep 30, 2025Nov 4, 2025 · pre-marketNov 4, 202535 d10-Q——-$0.447.9%
Q2 2025Jun 30, 2025Aug 5, 2025 · pre-marketAug 5, 202536 d10-Q——-$0.305.9%
Q1 2025Mar 31, 2025May 6, 2025 · pre-marketMay 6, 202536 d10-Q——-$0.273.4%
FY 2024
Q4 2024derivedDec 31, 2024Feb 25, 2025 · pre-marketFeb 25, 202556 d10-K———7.1%
Q3 2024Sep 30, 2024Nov 5, 2024 · pre-marketNov 5, 202436 d10-Q——-$0.24+16.5%
Q2 2024Jun 30, 2024Aug 6, 2024 · pre-marketAug 6, 202437 d10-Q——-$0.265.8%
Q1 2024Mar 31, 2024May 7, 2024 · pre-marketMay 7, 202437 d10-Q——-$0.25—
Earlier years, FY 2021 to FY 2023

Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Source filings

10-QNov 4, 2026122387
10-QAug 4, 2026090109
10-QMay 5, 2026055318
10-KFeb 11, 2026013044
10-QNov 4, 2025105939
10-QAug 5, 2025010203
10-QMay 6, 2025006497
10-KFeb 25, 2025001496
10-QNov 5, 2024014340
10-QAug 6, 2024010971

Provenance

ProvenanceData status and checks

Nuvectis Pharma, Inc. · CIK 1875558 · Engraved from SEC EDGAR